TerminatedPhase 4

Use of CXCL9 as a Biomarker of Acthar Efficacy

Stopped: sponsor closed study down

United States2 participantsStarted 2022-11-03

Plain-language summary

The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Biopsy-proven diagnosis of sarcoidosis with demonstrated pulmonary involvement * Refractoriness to or intolerance of immunosuppressive agents like prednisone or methotrexate Exclusion Criteria: * Smoking * Cancer * Chronic infections (e.g. tuberculosis, viral, fungal, bacterial) * Inflammatory conditions * Coexisting lung disease * Congestive heart failure * Uncontrolled hypertension * Recent surgery * Active peptic ulcers * Osteoporosis

What they're measuring

Number of Participants That Show a Decrease in Blood CXCL9 Levels by 50%

Timeframe: within 6 months

Trial details

NCT IDNCT02523092

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-31

Results submitted2026-01-06

View on ClinicalTrials.gov More Sarcoidosis trials